Biocon Biologics launches Yesintek Biosimilar to Stelara in US
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
This innovative platform is strategically essential to developing and scaling high-value life sciences use cases such as streamlining the content supply chain
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
Aster commits to increase bed capacity in the State via capacity expansion and greenfield projects
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
The Alathur facility specializes in the production of Cephalosporin antibiotics
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
Subscribe To Our Newsletter & Stay Updated